Literature DB >> 15961948

A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984-2004.

Neville V Jamieson1.   

Abstract

Primary hyperoxaluria (PH1) is a condition caused by a hepatic-based enzyme defect which can lead to renal failure due to oxalate stone disease, obstructive uropathy and nephrocalcinosis. It has been shown that the underlying metabolic defect can be corrected by liver transplantation and in most cases (renal failure having already occurred) is accompanied by a kidney graft. This paper describes the current results of 127 liver transplants performed in 117 patients over a 20-year period from 1984 to 2004 in 35 European centres. The mean age at onset of symptoms was 5.6 +/- 7.8 years and the mean age at which a diagnosis was made was 8.8 +/- 9.5 years. The diagnosis was confirmed by liver biopsy proven decreased AGT activity in 68% of cases, hyperoxaluria in 74%, hyperglycolicaciduria in 37% and hyperoxalaemia in 50%. Patients were transplanted at a mean age of 16.5 +/- 11.4 years following a period of dialysis of 3.2 +/- 3.2 years (range 0-14.4 years). 1-, 5- and 10-year patient survival values were 86, 80 and 69%, respectively, and liver graft survival rates of 80, 72 and 60% at the same time intervals. There have been 27 deaths and 10 liver retransplants have been carried out. Patient outcomes are improved when prolonged periods on dialysis and the complications of systemic oxalosis have not occurred.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961948     DOI: 10.1159/000086359

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  33 in total

Review 1.  Primary hyperoxaluria type 1: still challenging!

Authors:  Pierre Cochat; Aurélia Liutkus; Sonia Fargue; Odile Basmaison; Bruno Ranchin; Marie-Odile Rolland
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

2.  Combined liver and kidney transplantation in children: analysis of renal graft outcome.

Authors:  Randula Ranawaka; Carla Lloyd; Pat J McKiernan; Sally A Hulton; Khalid Sharif; David V Milford
Journal:  Pediatr Nephrol       Date:  2016-04-22       Impact factor: 3.714

3.  Hyperoxaluria and rapid development of renal failure following a combined liver and kidney transplantation: emphasis on sequential transplantation.

Authors:  Ahmed M Alkhunaizi; Nouriya A Al-Sannaa; Wasim F Raslan
Journal:  JIMD Rep       Date:  2011-09-06

Review 4.  Primary hyperoxalurias: diagnosis and treatment.

Authors:  Efrat Ben-Shalom; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-12-18       Impact factor: 3.714

Review 5.  Molecular therapy of primary hyperoxaluria.

Authors:  Cristina Martin-Higueras; Armando Torres; Eduardo Salido
Journal:  J Inherit Metab Dis       Date:  2017-04-19       Impact factor: 4.982

6.  Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1.

Authors:  Mónica Galanti; Angélica Contreras
Journal:  Pediatr Nephrol       Date:  2010-07-14       Impact factor: 3.714

7.  Liver transplantation in oxalosis prior to advanced chronic kidney disease.

Authors:  Jon I Scheinman
Journal:  Pediatr Nephrol       Date:  2010-07-29       Impact factor: 3.714

8.  Primary hyperoxaluria in a compound heterozygote infant.

Authors:  Juan Mayordomo-Colunga; Debora Riverol; Eduardo Salido; Fernando Santos
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

Review 9.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

10.  Pediatric combined liver-kidney transplantation: a single-center experience of 18 cases.

Authors:  Rémi Duclaux-Loras; Justine Bacchetta; Julien Berthiller; Christine Rivet; Delphine Demède; Etienne Javouhey; Rémi Dubois; Frédérique Dijoud; Alain Lachaux; Lionel Badet; Olivier Boillot; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2016-04-08       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.